Cellectis (NASDAQ:CLLS) Upgraded by StockNews.com to “Hold”

Cellectis (NASDAQ:CLLSGet Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

A number of other equities research analysts have also weighed in on the company. Robert W. Baird upgraded Cellectis from a “neutral” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, May 18th. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of Cellectis from a “buy” rating to a “hold” rating in a research report on Monday. The Goldman Sachs Group dropped their price target on shares of Cellectis from $3.00 to $2.00 and set a “sell” rating for the company in a research note on Tuesday. Finally, Barclays decreased their price objective on shares of Cellectis from $9.00 to $7.00 in a report on Friday, May 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $15.25.

Shares of CLLS traded up $0.21 during mid-day trading on Friday, reaching $3.98. 87,769 shares of the stock traded hands, compared to its average volume of 249,591. The firm has a market cap of $181.13 million, a price-to-earnings ratio of -1.35 and a beta of 2.24. The stock has a fifty day simple moving average of $3.94 and a 200 day simple moving average of $5.89. The company has a quick ratio of 3.73, a current ratio of 3.73 and a debt-to-equity ratio of 0.09. Cellectis has a 12-month low of $2.85 and a 12-month high of $16.53.

Cellectis (NASDAQ:CLLSGet Rating) last issued its quarterly earnings data on Thursday, March 3rd. The biotechnology company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.50. The firm had revenue of $13.66 million for the quarter, compared to analyst estimates of $12.30 million. Cellectis had a negative net margin of 312.64% and a negative return on equity of 53.48%. During the same quarter in the previous year, the business posted ($0.95) EPS. On average, equities research analysts expect that Cellectis will post -2.19 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Long Focus Capital Management LLC bought a new stake in Cellectis in the fourth quarter valued at $9,390,000. Jane Street Group LLC increased its holdings in shares of Cellectis by 166.5% in the 1st quarter. Jane Street Group LLC now owns 603,253 shares of the biotechnology company’s stock worth $2,789,000 after acquiring an additional 376,862 shares during the period. 683 Capital Management LLC lifted its position in Cellectis by 488.7% in the 4th quarter. 683 Capital Management LLC now owns 352,638 shares of the biotechnology company’s stock valued at $2,863,000 after purchasing an additional 292,738 shares during the last quarter. Capital International Investors boosted its stake in Cellectis by 18.9% during the 4th quarter. Capital International Investors now owns 1,592,054 shares of the biotechnology company’s stock valued at $12,927,000 after purchasing an additional 252,718 shares during the period. Finally, Legal & General Group Plc grew its position in Cellectis by 55.5% in the 4th quarter. Legal & General Group Plc now owns 337,201 shares of the biotechnology company’s stock worth $2,738,000 after purchasing an additional 120,369 shares during the last quarter. Hedge funds and other institutional investors own 40.55% of the company’s stock.

About Cellectis (Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Featured Articles

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.